PCOSAct试验:针刺与克罗米芬析因分析方法的修订与解释
PCOSAct试验旨在评估针刺和克罗米芬对多囊卵巢综合征(PCOS)患者的疗效。原方案采用三组两两比较,但实际数据分析发现标准析因分析方法更合适且统计效能更高,因此主要发表时改变了统计分析方法。修订后的方法聚焦两种干预的主效应及其交互作用,更符合析因试验特点且更精确。
要点
- PCOSAct试验采用2×2析因设计评估针刺和克罗米芬的主效应及交互作用。
- 原方案计划三组两两比较,实际分析改用标准析因分析,统计效能更高。
- 方法学修订虽偏离原方案,但更符合试验数据特征且结果更精确。
核心结论
- 采用标准析因分析评估针刺和克罗米芬的主效应及交互作用,比原方案的三组两两比较更合适、统计效能更高且更精确。
研究设计与样本
- PCOSAct是一项2×2析因设计的临床试验,注册号ChiCTR-TRC-12002081和NCT01573858。
主要发现
- 原方案设计为三组两两比较,但实际数据分析表明析因分析方法更合适且统计效能更高。
临床怎么用
- 对于2×2析因设计的临床试验,应优先采用析因分析评估主效应和交互作用,而非多个两两比较。
局限性
- 主要发表的统计分析方法偏离了原研究方案的计划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy of reproductive-aged women. Clomiphene is regarded as the first-line medical treatment for ovulation induction in PCOS patients and acupuncture is often used as an alternative and complementary treatment for fertility issues such as those associated with PCOS. The efficacy of acupuncture alone or combined with clomiphene still lacks strong supporting evidence. Factorial 2 × 2 designs can be used for the evaluations of two treatments within a single study, to test the main effects of acupuncture and clomiphene and their interactions. METHODS: PCOSAct was designed to test the effect of clomiphene and acupuncture by three two-group comparisons in the original protocol. However, the trial was designed as a standard factorial trial and the factorial analysis approach for analyzing the data that were actually obtained during the trial was found to be more appropriate and more powerful than the three two-group comparisons described in the original protocol, so the statistical analysis approach and different datasets of PCOSAct in the primary publication were accordingly changed. DISCUSSION: Although the statistical analysis approach used in the primary publication deviated from the statistical analysis planned in the study protocol, focusing on the main effects of the two interventions and their interactions was a more standard approach to a factorial trial and proved to be more suitable and consistent with the characteristics of the trial data. Statistically, the revision is more powerful and precise and should be more useful to the journal and the readers. TRIAL REGISTRATION: Chinese clinical trial registry, ChiCTR-TRC-12002081 . Registered on 20 March 2012. Clinicaltrials.gov, NCT01573858 . Registered on 4 April 2012.
引用
- Ma HL, Xie LZ, Gao JS, et al. Acupuncture and clomiphene for Chinese women with polycystic ovary syndrome (PCOSAct): statistical analysis approach with the revision and explanation. Trials. 2018. PMID: 30382872. doi:10.1186/s13063-018-2942-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。